Lauersen N H, Wilson K H
Obstet Gynecol. 1976 Jul;48(1):93-8.
Danazol in a dose of 400 mg daily was administrated to 40 patients with chronic cystic mastitis and resulted in a marded improvement in both objective and subjective symptoms in 87.5% of the patients studied. Three patients showed partial relief of symptoms and 1 patient showed no improvement after 1 month of treatment at which time she withdrew from the study. One patient had a worsening of her condition and was withdrawn from the study after 3.5 months of therapy. Nineteen of the 40 patients in the study had a secondary diagnosis of pelvic endometriosis confirmed histologically, and all these patients showed a marked improvement of symptoms during the Danazol treatment. Patients developed amenorrhea after 3 to 4 months of Danazol therapy, and symptoms such as dysmenorrhea, premenstrual pelvic pain, and tension abated at the same time. A mild, but well-tolerated weight gain was the major side effect of Danazol administration. No significant changes in the levels of plasma E1, E2, FSH, LH, or progesterone could be demonstrated in specimens drawn from 11 patients before and during the course of Danazol administration.
对40例慢性囊性乳腺炎患者每日服用400毫克达那唑，结果显示，在接受研究的患者中，87.5%的患者的客观和主观症状都有显著改善。3例患者症状部分缓解，1例患者在治疗1个月后无改善，此时退出研究。1例患者病情恶化，在治疗3.5个月后退出研究。研究中的40例患者中有19例经组织学确诊为继发性盆腔子宫内膜异位症，所有这些患者在达那唑治疗期间症状均有显著改善。达那唑治疗3至4个月后患者出现闭经，同时痛经、经前盆腔疼痛和紧张等症状减轻。体重轻度增加但耐受性良好是服用达那唑的主要副作用。从11例患者服用达那唑之前和服药过程中采集的样本中，未发现血浆E1、E2、FSH、LH或孕酮水平有显著变化。
